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Background: Despite rendering serum free thyroxine (FT4) and thyrotropin (TSH)
within the normal population ranges broadly defined as euthyroidism, many patients
being treated for hyperthyroidism and hypothyroidism persistently experience
subnormal well-being discordant from their pre-disease healthy euthyroid state. This
suggests that intra-individual physiological optimal ranges are narrower than
laboratory-quoted normal ranges and implies the existence of a homeostatic set
point encoded in the hypothalamic-pituitary-thyroid (HPT) axis that is unique to
every individual.
Methods: We have previously shown that the dose–response characteristic of the
hypothalamic-pituitary (HP) unit to circulating thyroid hormone levels follows a
negative exponential curve. This led to the discovery that the normal reference
intervals of TSH and FT4 fall within the ‘knee’ region of this curve where the
maximum curvature of the exponential HP characteristic occurs. Based on this
observation, we develop the theoretical framework localizing the position of euthyroid
homeostasis over the point of maximum curvature of the HP characteristic.
Results: The euthyroid set points of patients with primary hypothyroidism and
hyperthyroidism can be readily derived from their calculated HP curve parameters
using the parsimonious mathematical model above. It can be shown that every
individual has a euthyroid set point that is unique and often different from other
individuals.
Conclusions: In this treatise, we provide evidence supporting a set point-based
approach in tailoring euthyroid targets. Rendering FT4 and TSH within the laboratory
normal ranges can be clinically suboptimal if these hormone levels are distant from the
individualized euthyroid homeostatic set point. This mathematical technique permits
the euthyroid set point to be realistically computed using an algorithm readily
implementable for computer-aided calculations to facilitate precise targeted dosing of
patients in this modern era of personalized medicine.
Keywords: Hypothalamus-pituitary-thyroid axis, Log-linear, Feedback, Personalized
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The enigma of symptomatic ‘euthyroidism’
Thyroid stimulating hormone [TSH] and free thyroxine [FT4] constitute most standard
thyroid function tests (TFT) and play a central role in the process of diagnosis and
treatment of thyroid diseases such as hypothyroidism and thyrotoxicosis. Evidence indi-
cates that the laboratory-quoted [TSH] reference range is not always appropriate for
everyone in clinical practice [1-5]. Clinicians recognize a common phenomenon of pa-
tients who persistently experience residual symptoms of thyrotoxicosis or hypothyroidism
despite having achieved circulating levels of [FT4] and [TSH] within the normal ranges
[4,6-8]. Hence, achieving a [TSH] within a healthy range may still depart significantly
from the true euthyroid set point of any given individual [4].
To solve this problem, it is crucial to appreciate that the normal operation of a nega-
tive feedback loop implies the existence of a point of reference, or a set point intrinsic
to the system [9-12]. The HP unit acts as a sensitive metabolic sensor and master
controller for regulating the thyroid output to a very narrow physiological ‘set range’
(termed the homeostatic set point) appropriate to the individual at euthyroidism.
Any departure of [FT4] and [TSH] away from this set point leads to a disequilibrium
that influences the HP unit to alter its response so as to restore the system back towards
the set point [13]. In this servo-control system, the set point in an intact hypothalamus-
pituitary-thyroid (HPT) axis of a healthy euthyroid individual represents the ideal ‘person-
alized’ TFT target that results in an optimal healthy state.
In physiology, both optimal control and steady states are critical for survival and good
health. Homeostatic mechanisms operate with great efficiency to restore equilibrium from
acute perturbations. However, various biological constraints due to disease or environment
changes may lead to failure of achievement of the steady state and physiological optimum.
In the terminology of systems theory, a system in steady state has numerous characteristics
that are constant over time such that the partial derivative of these characteristics with re-
spect to time is zero and the recently observed behavior of the system will continue into
the future. The steady state is usually not attained till sometime after an initial ‘transient
warm up’ period. Notably, the steady state is more general than dynamic equilibrium in
that the former may not be a state of dynamic equilibrium as some processes are irrevers-
ible while the latter is always a steady state in which the forward and reverse processes are
occurring at the same rate. Optimal feedback control refers to the process of determining
the control and state trajectories for a dynamic system over time to maximize or minimize
a performance index while satisfying specified constraints where the control variables are
determined as functions of the current state of the system, a principle widely exploited as
part of Nature’s strategies to confer the best probabilities for survival.
For the HPT axis, optimal feedback control and systems theory explain how thyro-
tropic hormones are governed and maintained within a preferential normal range that
allows people to live and enjoy good health. In individuals whose HPT feedback loops
have been disrupted by diseases, we hypothesize that their state of health may be re-
stored back to the original, provided that their [FT4] and [TSH] are driven towards
their pre-disease set points. Molecular, tissue, biochemical and clinical euthyroidism
appropriate to the individual, will ultimately be achieved when the [FT4] and [TSH]
are both therapeutically constrained to dwell within the set point and its immediate
vicinity over a sufficiently long timeframe.
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Mathematical modeling of the HP function had previously yielded an inverse exponen-
tial law governing the [TSH] and [FT4] relationship which is sigmoidal in profile with
an inflexion point that can be approximated by a negative exponential curve in most
practical instances [14]. This fits the well established observation of an approximately
log-linear function between [TSH] and [FT4] that to date remains the best biophysical
first principle coupling these two hormones’ concentrations [15-21]. Hence, we derived an
individualized [FT4] – [TSH] relationship (hereby termed the hypothalamic-pituitary
(HP) function) using a minimal model based on a parameterized negative exponential
model of the HPT axis with two degrees of freedom that opens up a novel approach for
precise individualized dosing of levothyroxine (L-T4) substitution and anti-thyroid drug
(ATD) therapy [22,23].
A key observation we discovered, is the consistent localization of the normal popula-
tion ranges of [TSH] and [FT4] values within the “knee” region coinciding to the most
pronounced bend on the negative exponential plot of the HP function on the TSH-FT4
Cartesian plane [22]. The obvious implication of this discovery is that the euthyroid set
point must be localized somewhere over this region that optimizes the system’s control
ability of the HPT axis to calibrate the [TSH] output robustly for tight homeostasis
within a narrow physiological window for survival advantage. This leads us logically to
conjecture that the euthyroid set point of the HPT axis should correspond to the point
of maximum curvature of the HP function for optimal efficiency in homeostatic con-
trol. We evaluate this postulate from a mathematical perspective and validate it using
clinical data. An independent confirmation is shown in a HPT loop gain optimization
analysis according to control theory principles [13]. With these results, we devise the
foundations of a novel approach to improve diagnostics and the related therapeutic
strategies for hypothyroid and hyperthyroid patients.
Although triiodothyronine [T3] is the main active thyroid hormone, the response
characteristics analysis as confined purely to the relationship between [FT4] and
[TSH] is sufficient for all intents and purposes. This is valid because the local DIO2
(type II 5’-deiodinase) in the hypothalamus and pituitary converts [FT4] into [T3]
locally, which together with ambient circulating [T3] contributed by peripheral
DIO1 (type I 5’-deiodinase)-mediated deiodination of [FT4] and by direct thyroidal
secretion of [T3], then exerts negative feedback signal responsible for the inhibition of
[TSH]. Moreover, a model involving key observable variables of interest (primarily [FT4]
and [TSH]) is pragmatic and will thus find the widest clinical application. In contrast, any
modeling attempt incorporating [T3] or [FT3] to encompass a more complete picture ac-
tually suffers from the serious drawback of severely limited practical utility as both [T3]
and [FT3] are generally measured only in specific clinical situations rather than routinely
in the assessment and monitoring of thyroid status [6].
Methods
Parameterization of the negative exponential HP characteristic
As mentioned above, the properties and form of the HP characteristic have been de-
rived from fundamental physiological considerations [14]. This theory led to our con-
struct of two independent HP model parameters. The parameterized expression linking
the concentrations of the [TSH] and [FT4] is:
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This model has been published [22] and also clinically validated in another paper [23]
This characteristic has been described as a 2-dimensional (S and φ) model where parame-
ters S and φ are real positive numbers which are derived from measured individualized
thyroid function tests.
One and only one exponential function is completely defined by the coordinates of
two different points P1 and P2 in the [FT4]-[TSH] plane according to
φ ¼ 1








S ¼ TSH½ 1 exp φ FT4½ 1
  ¼ TSH½ 2 exp φ FT4½ 2  ð2:0:3Þ
P1 ¼ FT4½ 1; TSH½ 1
 
and P2 ¼ FT4½ 2; TSH½ 2
  ð2:0:4Þ
Every exponential function has a unique identifiable point of maximum curvature
from which the complete function can be reconstructed as elaborated below. Thus, the
HP function can also be determined by that single specific point. The accuracy of S and φ
is dependent on the fitting quality of the exponential function as discussed in detail else-
where [22]. This relates also to the definition and qualification of possible outliers [24].
Calculation of the set point of the HPT axis from a defined HP function
In this treatise, the set point for euthyroid homeostasis in the HPT axis feedback loop
is postulated to occur in the point of the HP function where the sensitivity for any
change around this point on the curve is maximal. This point of maximum curvature
and thus maximal sensitivity for change can be found according standard curvature
theory. The radius of curvature at a point of a function is defined as R and the curva-




If the function to be examined is defined as y = f (x) = f1 then the curvature K of y is
defined as






Using the HP function of the hypothalamic-pituitary unit, we haveTSH½  ¼ S exp −φ FT4½ ð Þ ð2:0:7Þ
Writing [TSH] = y and [FT4] = x, we have
y ¼ S exp −φxð Þ ð2:0:8Þ
Working out (2.0.8) according to (2.0.6), we findK ¼ φ
2S exp −φxð Þ
1þ φ2S2 exp −2φxð Þ 3=2 ð2:0:9Þ
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thenf 3 ¼ dK
dx
¼ φ
3S exp −φxð Þ 1þ φ2S2 exp −2φxð Þ 	0:5 2φ2S2 exp −2φxð Þ−1
 
1þ φ2S2 exp −2φxð Þ 	3 ; ð2:0:11Þ
or2φ2S2 exp −2φxð Þ−1 ¼ 0;
resulting inexp −2φxð Þ ¼ 1
2φ2S2
;
from which we find






















Notably, the euthyroid set point has been derived from the model parameters of the
HP function with coordinates on the FT4-TSH plane given by the ‘Leow-Goede equa-
tions’ as follows:











Physiological theory of the homeostasis process
In Figure 1, the functions of the HP (f1) black curve, the function for the curvature
of f1: (f2) red curve and the derivative of the curvature (f3) blue curve are shown in
one graph. In this example, the reference ranges used are 10 ≤ [FT4] ≤ 20 pmol/L and
0.4 ≤ [TSH] ≤ 4 mU/L.
If we write for the variable [FT4] = x
The curvature function:
Figure 1 HP function (f1), curvature function (f2) and derivative of f2 (f3). For illustrative purposes,
[FT4]sp (set point) and [TSH]sp (set point) which respectively represent the values of [FT4] and [TSH] where
the euthyroid set point occurs are 15 pmol/L and 1.6 mIU/L respectively. These set point values correspond
to φ ¼ 1
TSH½  ﬃﬃ2p ¼ 0:442 and S = [TSH]exp(φ[FT4]) = 1211.
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2S exp −φxð Þ
1þ φ2S2 exp −2φxð Þ 3=2 ð2:0:17Þ
The theory for the maintenance of homeostasis around the set point is as follows.




Here, we find two extremes of f3: at [FT4]1 and [FT4]2 which occurs respectivelybelow and above [FT4]sp, as indicated in Figure 1. [FT4]1 and [FT4]2 function as re-
pulsion boundaries signaling the HP unit to fine-tune the feedback regulation of TSH
secretion. When the [FT4] level is increasing and passes [FT4]sp, the HP unit measures
both [FT4] and the gradient of f3, and uses the criteria of [FT4]2 together with the
change in gradient of f3 from negative through zero to positive to disable the thyroid
hormone production when the [FT4] concentration rises beyond [FT4]2. The thyroid
hormone production rate will thus decelerate and the [FT4] concentration will accord-
ingly decrease. Then the decline of [FT4] will cross [FT4]sp and fall towards [FT4]1.
The HP unit then detects the [FT4]1 level and a change in gradient of f3 from negative
through zero to positive to enable an up-regulation of [TSH] to counteract this situ-
ation, thereby resulting in an increase in [FT4] again towards [FT4]sp. This dynamic
control mechanism based on gradient-curvature detection is quite similar to a modulating
regulator with hysteresis as found in advanced thermostats. Essentially, the point of max-
imum curvature of the HP curve provides the highest sensitivity for [TSH] responses to
changes in [FT4] levels such that the vector of [FT4] is always dynamically poised towards
a predetermined stable euthyroid homeostatic set point deemed optimal for survival.
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We can better appreciate and understand this robust control and calibration of [FT4]
and [TSH] by an intact HPT axis towards euthyroidism in a healthy biological system
by applying the notion of a control system represented by the HP unit and the thyroid
coupled in a feedback loop. The control system is governed by the HP controller char-
acteristic, unique for every individual like a fingerprint. In this control loop, the HP is
the main ‘master’ controller and the thyroid behaves as a ‘slave’ accommodating to the
secretory demands, both in rate and magnitude, resulting in two independent thyroid
secretory parameters, A and α, such that the loop gain is optimized for the set point
position. The loop gain is defined as the modulus of the product of the HP gain factor
and the thyroid gain factor. The value of the loop gain is dimensionless and has to be
greater than unity in order to maintain optimal and stable control [25]. The loop gain
has an optimum coinciding with the set point for stability of the feedback loop which
will be proved.
The HP transfer function as mentioned in section Parameterization of the negative
exponential HP characteristic:
TSH½  ¼ S exp −φ FT4½ ð Þ ð2:0:19Þ
The HP gain factor is defined as the first derivative of the HP transfer characteristic noted asGHP ¼ d TSH½ d FT4½  ¼ −φS exp −φ FT4½ ð Þ ¼ −φ TSH½  ð2:0:20Þ
The thyroid transfer characteristic is derived from a Michaelis-Menten model [26].This model can be further modified to a saturating exponential expression which provides a
more realistic representation of the thyroid behavior and can be parameterized using two
independent model parameters, A and α. Parameter A defines the upper asymptotic
secretory [FT4] level and α represents the steepness with which the saturation level is
reached as a function of the variable [TSH]. The output signal of the thyroid is repre-
sented by [FT4]. The function is written as:
FT4½  ¼ A 1− exp −α TSH½ ð Þf g ð2:0:21Þ
Here, A and α are the independent model parameters of the thyroid transferfunction.
The thyroid gain factor GT can be determined as:
GT ¼ d FT4½ d TSH½  ¼ −αA exp −α TSH½ ð Þ ð2:0:22Þ
The loop gain GL is defined as the modulus of the product |GHPGT| resulting in:GL ¼ GHPGTj j ¼ φ TSH½ αA exp −α TSH½ ð Þ ð2:0:23Þ
We note that GL is solely a function of the variable [TSH]. We can examine the prop-
erties of GL related to an optimum value. For this purpose, we determine the first de-
rivative of GL to [TSH] and examine the solution when this equals zero.
dGL
d TSH½  ¼
φαA−φα2A TSH½ 
exp α TSH½ ð Þ ¼ 0 ð2:0:24Þ
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because the loop gain GL is a function of that variable. It follows that at optimum GL,






Using the original expression for the thyroid,
FT4½ setpo int ¼ A 1− exp −α TSH½ setpo int
 n o
; ð2:0:27Þ
and substituting the result for α, we have:








with e = 2.7182, we then find A:A ¼ FT4½ setpo int
0:632
ð2:0:29Þ





Based on these relationships, the thyroid will operate such that the loop gain will beoptimal at the set point. This means the thyroid accommodates to both the demands of
secretory amplitude (A) and steepness (α). In a calculation example, we demonstrate
the properties of the optimum in the loop gain belonging to the set point, [FT4] = 15
pmol/L and [TSH] = 1.6 mU/L.
This results in α ¼ 1TSH½  ¼ 11:6 ¼ 0:625 and from (2.0.29), we derive:





As earlier shown in Figure 1, we found according to the set point equations S = 1211and φ = 0.442.
The exponential thyroid model is thus:
FT4½  ¼ 23:73 1− exp −0:625 TSH½ ð Þf g
The thyroid function to be depicted in an inverted axis superimposed into the same
plot as the HP function, because the common variable is [TSH], results in:
TSH½  ¼ 1:6 ln 15
15−0:632 FT4½ 
 
The loop gain function was derived before as:
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As depicted in Figure 2, the first derivative of GL declines to zero exactly over the
[TSH] value of 1.6 mU/L at which the maximum of the loop gain occurs. As can be
checked by the application of:
GLmax ¼ φAe ; ð2:0:33Þ
this maximum loop gain equals 3.85.
This shows that the absolute value of the loop gain decreases when [TSH] deviates
from the set point value. This negative feedback loop itself will maintain this stable
condition for homeostasis.
The euthyroid set point in this example is shown by the negative exponential curve
defined by parameters S = 1211 and φ = 0.442 (ie. TSH = 1211 exp (−0.442[FT4])).
From these parameters, the set point at the maximum curvature of this HP curve is:
[FT4] = 15 pmol/L and [TSH] = 1.6 mU/L. When we substitute [FT4] = 15 pmol/L into
equation (2.0.21), we find [TSH] = 1.6 mU/L, which also satisfies the condition of the
set point occurring at the intersection of the HP characteristic curve and the inverted
thyroid characteristic derived from (2.0.21):







This intersection (Figure 3) is the mathematical solution of these two simultaneousnon-linear equations and corresponds to the concentration of [TSH] which stimulates
just the appropriate [FT4] output which in turn feedback negatively to keep [TSH]
exactly at this stationary input level. Hence, this is a necessary and sufficient condition
for stable equilibrium and physiologically represents the homeostatic euthyroid set
point, thereby proving yet again that this state indeed overlies the point of maximum
curvature of the HP function. The set point from optimal control perspectives is analogousFigure 2 Plot of loop gain as a function of TSH (solid line). This shows a maximum loop gain at the set
point while the first derivative of the loop gain is illustrated by the dotted line.
Figure 3 The homeostatic euthyroid equilibrium point. The set point occurs at the intersection of the
HP (black) and the inverted thyroid (blue) functions coinciding with the maximum curvature of the
HP function.
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and efficiency in the steady state as also demonstrable in other physiological systems [27].
Sensitivity analysis of exponential model parameters
Based on the formulation describing the [FT4]-[TSH] characteristic, when two (or more)
measured points (eg. ([FT4]1, [TSH]1) and ([FT4]2, [TSH]2)) from an individual are
distinctly separated on the [FT4]-[TSH] plane such as typically observed during the
dose titration process of treatment, it is possible to calculate the HP characteristic
based on parameters S and φ as follows:
φ ¼ 1








S ¼ TSH½ 1 exp φ FT4½ 1
  ¼ TSH½ 2 exp φ FT4½ 2  ð2:0:36Þ
We will distinguish the various dependencies of φ and S in relation to [FT4] and[TSH] as follows. The dependency of φ for variations in [FT4] holding [TSH] constant,
can be written as:
φ ¼ 1
FT4½  ð2:0:37Þ
in Figure 4A indicated as red curve.
The dependency of φ for variations in [TSH] holding [FT4] constant, can be written as




This dependency is depicted in Figure 4B as a solid red curve.
Figure 4 Sensitivity analysis of S and φ A) Parameter variations as a function of [FT4] and B)
Parameter variations as a function of [TSH].
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can be depicted by the solid red graph shown in Figure 4A while the effect of fluctua-
tions of [TSH] on φ (ie. equation (2.4.2)) is shown by the solid red graph of Figure 4B.
From these graphs, we can determine the partial derivatives which represent the
gain factor for small deviations around a certain point on either the blue or the red
curve. Thus,
∂φ
∂ FT4½  ¼
−1
FT4½ 2 ; ð2:0:39Þ
shown in Figure 4A
∂φ
∂ TSH½  ¼
−1
TSH½  ; ð2:0:40Þ
shown in Figure 4B.
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rapidly when FT4 < 2 pmol/L, whereas variations in [TSH] < 0.5 mU/L will contribute
to relatively large errors in φ. For S, we find the following:
∂S
∂ TSH½  ¼ 1 ð2:0:41Þ
as a straight dashed blue line in Figure 4B and
∂S
∂ FT4½  ¼ exp FT4½ ; ð2:0:42Þ
as depicted in Figure 4A in dashed blue which fully coincides with the blue curve.Errors in S estimation are independent of [TSH] but escalate with increasing [FT4].
Fortunately, modern FT4 assays are robust to errors while third generation TSH assays
are sensitive and precise.
Clinical examples in this paper illustrate that S and φ estimates are reassuringly ac-
curate in practice for the purpose of elucidating the set point to guide individualized
therapeutic targets.
Ethical approval, laboratory assays and statistical analysis
For the purpose of clinical validation of this theoretical framework, a group of normal
euthyroid individuals (N = 14) were randomly sampled and their TFTs were traced to
assess if [FT4] and [TSH] of each individual essentially remained stable over time
(Table 1). Another patient group (N = 70) with thyroid disease on medication were ran-
domly selected to validate the set point theory. All clinical dataset in this study was
acquired with ethical approval (National Healthcare Group Domain Specific Review
Board (DSRB ‘C’) ethics committee, C/2011/02012) from individuals under follow-up
by the co-author (MKSL) in the Department of Endocrinology at Tan Tock Seng Hospital
of Singapore. Serum TSH and FT4 were assayed in the clinical chemistry laboratory of
the same hospital using manufacturer-supplied standard reagents, calibrators and controls
from Beckman Coulter, Krefeld, NRW, Germany, on two Beckman Coulter DxI800
automated immunoassay analyzers. The intra-assay and inter-assay CVs for both
TSH and FT4 are less than 10% and the normal reference intervals for FT4 and TSH
are 8–21 pmol/L and 0.34-5.6 mIU/L respectively.
We have to take into account that the datasets in the results section are not optimized
for accuracy and reproducibility as we have discussed in a recent paper about the optimal
conditions for the HP model [22]. Nonetheless, the data serve well to prove our set point
conjecture. All statistical analyses were conducted using the statistical program Stata
(Release 13, StataCorp. College Station; Texas: StataCorp LP).
Results
Stability and uniqueness of the HPT axis euthyroid set point
Before we proceed to apply the theory of the homeostatic euthyroid set point as de-
scribed above to patients with thyroid hormonal disorders, it is insightful to understand
the properties of the euthyroid set point as it functions in healthy individuals. Assuming
that this set point has been programmed by factors including growth, body weight, energy
supply, metabolic rate and the complex nexus of genes-environment interactions such
Table 1 Healthy euthyroid subjects showing their stability of their TFTs over time
Patient TFT paired results (FT4, TSH) over time Similarity metric
1 (S25) Date: Apr ‘07 Aug ‘09 Dec ‘09 Jan ‘10 Mar ‘11 0.3679
FT4: 9 9 8 10 10
TSH: 1.59 1.71 1.34 1.87 1.69
2 (S26) Date: Sep ‘01 May ‘02 0.9861
FT4: 12 12
TSH: 0.89 0.71
3 (S27) Date: Jun ‘07 Apr ‘ 08 Feb ‘10 0.5504
FT4: 11 11 12
TSH: 1.00 1.03 1.02
4 (S42) Date: Nov ‘10 Jun ‘12 Feb ‘13 0.6138
FT4: 10 10 10
TSH: 3.25 2.40 2.43
5 (S18) Date: Apr ‘06 Jul ‘12 0.5858
FT4: 10 11
TSH: 1.89 1.90
6 (S20) Date: May ‘97 Sep ‘00 Jul ‘05 Feb ‘08 Oct ‘11 0.4114
FT4: 16 15 16 16 15
TSH: 1.31 1.08 1.57 1.24 1.35
7 (S22) Date: Aug ‘02 Oct ‘11 Jun ‘12 0.5484
FT4: 13 14 12
TSH: 1.16 1.46 1.26
8 (S23) Date: Feb ‘10 Nov ‘10 Nov ‘11 0.3003
FT4: 12 11 11
TSH: 0.71 0.85 0.83
9 (S10) Date: Apr ‘04 Dec ‘05 Nov ‘06 Aug ‘07 0.4109
FT4: 13 11 11 10
TSH: 0.92 1.87 1.73 1.96
10 (S13) Date: Aug ‘03 Mar ‘06 Jul ‘12 0.3729
FT4: 10 9 11
TSH: 1.66 1.38 1.68
11 (S15) Date: Oct ‘06 Jan ‘09 Dec ‘09 Oct ‘10 Sep ‘12 0.4074
FT4: 13 11 11 12 12
TSH: 0.84 0.69 0.90 0.77 0.87
12 (S09) Date: Nov ‘05 Oct ‘06 Jul ‘11 Jun ‘12 0.4647
FT4: 11 10 9 10
TSH: 1.53 1.99 1.68 1.85
13 (S49) Date: Mar ’11 Mar ‘13 0.5857
FT4: 12 13
TSH: 0.84 0.8
14 (S53) Date: Sep ’05 Mar ’12 Jul ‘13 0.3492
FT4: 13 11 13
TSH: 1.18 2.45 1.83
Normal [FT4] reference range: 8 ≤ [FT4] ≤ 21 pmol/L and for [TSH]: 0.34 ≤ [TSH] ≤ 5.6 mU/L.
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the [FT4] and [TSH] surrounding the set point should remain relatively stable even over
an extended period of time across the lifespan of the individual. This euthyroid set point
(or ‘set range’) is thus expected to be tightly regulated with a physiological window far
narrower than the usual normal population reference ranges of [FT4] and [TSH] and is
likely to be unique in any given person.
It is remarkable that each person, when healthy, continues to show TFTs that are
closely clustered together even after a decade later as shown in Table 1. To evaluate
closeness of 2-D data points, the Euclidean distance (ED) is employed [28]. This can be
normalized to a ‘similarity metric’, a basic measurement of the degree to which two ob-
jects are alike, by taking the reciprocal of ED:
Similarity metric ¼ 1
1þ ED ; ð2:0:43Þ
such that the values returned by this computation lie between 0 and 1, whereby 0means no similarity and 1 implies complete similarity [29]. Virtually every individual
exceeded 0.3, indicating a very strong intra-personal TFT clustering effect. Further-
more, statistical analysis using the multi-level regression with a general structural equa-
tion modeling framework (GLLM) [30] revealed the heterogeneity between subjects to
be 0.0107 (95% CI: 0.0029-0.03975, p < 0.05). Each TFT pair is both tightly clustered
intra-individually and distinctly separate from one another (Figure 5), supporting our
hypothesis that everyone has a unique and stable euthyroid set point.
Given that the [FT4] data in Table 1 are either rounded off or had decimals truncated
results from original assay readouts (often up to one decimal accuracy), these values
can be interpreted as [FT4] ± 1 [6,22]. For [TSH] in Table 1, we can assume that the













Figure 5 Multi-level regression model of the dataset in Table 1 (gamma distribution and log link;
random intercept and slope model). TFTs are level 1 while subjects are level 2. Rectangles represent
observed variables and ovals represent latent variables. Numbers represent variance, covariance, regression
coefficient and constant.
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As shown above, there is strong evidence that the euthyroid set point is relatively constant
and stable in most healthy people at least over a span of one to two decades. From a teleo-
logical perspective, it benefits long-term health for physiological functions driven by meta-
bolically potent thyroid hormones to be optimally regulated within feedback threshold
hormonal levels encompassing the euthyroid set point and its surrounding narrow neigh-
borhood for maximal disease-free survival. Our theoretical modeling has clearly
demonstrated the natural tendency of such a set point to be robustly defended at
the point of maximum curvature of the HP function. Clearly, it is still crucial to val-
idate the model with supporting clinical data. In an intact HPT axis, the closed feed-
back loop controls the [FT4] and [TSH] to the set point and thus obscures the
unique negative exponential HP function necessary to test the theory. It requires a
pathological thyroid state to break open the closed loop and unravel the HP character-
istic for testing. A number of independent methods as listed below may be employed by re-
searchers keen to study the validity of this set point theory, with the caveat that some could
be considered challenging to perform, logistically unfeasible or possibly ethically untenable
depending on the circumstances.
Methods of clinical validation
In ascending order of difficulty and feasibility, the following are various methods of
clinical validation strategies that may be employed to test the set point theory:
(1) Tracking the TFTs during the treatment of those with total thyroidectomy
(eg. thyroid cancer, massive multinodular goiter, etc.) who require life-long L-T4;
their original euthyroid pre-operative FT4-TSH levels would be considered their
original set points that can be compared to the set points calculated using their
plotted HP curves.
(2) Patients with Graves’ disease who successfully achieved a sustained long term
clinical remission after successfully weaning off antithyroid drugs; their TFTs
during remission may be considered their euthyroid set points which can be
compared with the set point values computed from their HP curves while they
were previously still on treatment.
(3) Patients presently on anti-thyroid drugs for hyperthyroidism or L-T4 for
hypothyroidism with a prior historical record of previously normal euthyroid FT4-TSH
data long before the onset of thyroid disease that subsequently requires definitive
thyroid-specific treatment and dose adjustments, whereupon their computed set points
on their HP curves can be matched against their original normal FT4-TSH data.
(4) Searching existing epidemiologic literature with published laboratory data
documenting the natural history of those screened positive for thyroid
autoimmune markers associated with an euthyroid state initially and who then
subsequently develop thyroid disease requiring treatment.
(5) Patients who received radiation therapy of the neck for cancers (eg. lymphomas,
parotid gland carcinoma or nasophayngeal cancer) who then developed hypothyroidism
allowing HP curves to be plotted and set points computed; any euthyroid TFTs
pre-radiotherapy would serve as a benchmark for comparison with the computed
set points.
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using thionamides and/or administered either L-thyroxine (L-T4) or
liothyronine (L-T3) to induce experimental thyrotoxicosis according to
ethically approved safe research protocols (depending on the jurisdiction
of institutional review boards) in order to generate unique HP curves for set
points determination which can then be compared against their own natural
set points.
(7) Unusual patients with “euthyroid Graves’ disease”, whose TFTs are consistently
within the normal ranges could arguably be considered euthyroid set points due to an
equimolar mixture of TSH receptor stimulating and blocking autoantibodies with a
‘tug-of-war’ stoichiometric ratio resulting in euthyroidism; subsequent development
of thyrotoxicosis or hypothyroidism due to antibodies imbalance allows HP curves to
be plotted for set point computations.
(8) Prospective follow-up of euthyroid people positive for thyroid autoantibodies
(with previous euthyroid TFTs prior to developing thyroid autoimmunity)
over years until their thyroid dysfunction manifests, after which the
calculated set points on their respective HP curves can be compared with
their initial euthyroid TFTs.
Examples of clinical data validating set point calculations
The following clinical data formally illustrate and constitute an elegant proof-of-
concept of our set point theory. We demonstrate five case examples (out of a total of
N = 70 cases) to allow an in-depth analysis of the set point confirmation with real
clinical data. However, the remaining cases are summarized graphically as shown in
Figure 14A-D and Figure 15.
Case 1: 53 yr old Chinese woman P11 (LMC)
This patient has bipolar affective disorder treated with lithium by her psychiatrist two
years ago. This precipitated overt symptomatic hyperthyroidism. Serial paired FT4
(in pmol/L) and TSH (in mU/L) and drug dosing (Rx) with carbimazole (CMZ in mg)
and levothyroxine (L-T4 in μg) are:Her thyroid was ablated with 18 mCi of radioiodine-131, following which CMZ could
be stopped while LT4 started. She has some cold intolerance when FT4 was 10 pmol/L
but felt better as her FT4 started rising above 10 pmol/L.
Her pre-lithium euthyroid TFT six years ago was: FT4 = 14.6 pmol/L and TSH =
1.72 mU/L which matched the calculated set point closely (FT4 = 14.28 pmol/L and
TSH = 2.00 mU/L) (Figure 6). The outliers falling outside the expected range of the
model selection were excluded [24].
Figure 6 Set point tracing of patient P11 (LMC).
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This patient was diagnosed with Graves' disease two months after the develop-
ment of pretibial myxoedema. After a two-year course of antithyroid drug (ATD)therapy with CMZ, her serum TSH receptor autoantibody (TRAb) fell below im-
munoassay detection limit of < 0.4 U/L when CMZ was tapered off and she
remained in full remission till today.
The computed euthyroid set point is FT4 = 14.7 pmol/L and TSH = 1.37 mU/L
(Figure 7). This patient’s own historical TFT record showed a euthyroid FT4 = 16.1
pmol/L and TSH = 1.43 mU/L done 15 months before she contracted Graves’ dis-
ease. There is relatively satisfactory agreement between the predicted set point and
the actual euthyroid set point of the patient. The excluded outliers are out of the
range of the model selection because of significant hysteresis effect whereby TSH
gene expression remains subnormal for any given FT4 following recent
hyperthyroidism.
Figure 7 Set point tracing of patient P53 (AL).
Leow and Goede Theoretical Biology and Medical Modelling 2014, 11:35 Page 18 of 30
http://www.tbiomed.com/content/11/1/35Case 3: 69 yr old Chinese woman P31 (SSPG)
This woman was well till some 5 years ago when she consulted a rheumatologist for
stenosing tenosynovitis and carpal tunnel syndrome. As part of the investigative
workup, TFT was done which showed borderline FT4 and elevated anti-thyroperoxidase
autoantibodies (TPO Ab > 500 U/L). Given that TPO Ab predicts a risk of thyroid failure,
annual TFTs were serially monitored. Her TFT a decade ago during a health screening was
normal: FT4 = 12 pmol/L and TSH= 1.53 mU/L.
The computed set point is FT4 = 10.1 pmol/L and TSH = 2.02 mU/L (Figure 8). This
estimate is roughly concordant with her original euthyroid set point.Figure 8 Set point tracing of patient P31 (SSPG).
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This patient has a history of laryngeal squamous cell carcinoma for which he underwent
total laryngectomy with radical neck dissection followed by adjuvant chemo- and radiother-
apy. His pre-surgery, pre-radiotherapy TFT was FT4 = 17.8 pmol/L and TSH= 0.88 mU/L
which can be considered his original euthyroid set point. His subsequent TFTs post-cancer
treatment were:From the computed set point (FT4 = 15.35 pmol/L and TSH = 1.45 mU/L) (Figure 9)
and his initial euthyroid TFT (FT4 = 17.8 pmol/L and TSH = 0.88 mU/L), it can
be concluded that the predicted set point was reasonably close to his original
normal TFT.Figure 9 Set point tracing of patient P68 (KST).
Figure 10 Set point tracing of patient P45 (LBH).
Leow and Goede Theoretical Biology and Medical Modelling 2014, 11:35 Page 20 of 30
http://www.tbiomed.com/content/11/1/35Case 5: 52 yr old Chinese woman P45 (LBH)
This woman was healthy and well until 2004 when she discovered a painless right thyroid
swelling.
She was clinically and biochemically euthyroid (pre-operative FT4 = 13.0 pmol/L and
TSH = 1.35 mU/L). Thyroid ultrasonography revealed a solid-cystic nodule and fine
needle biopsy showed a suspicious follicular lesion. She underwent right thyroid lobectomy
which showed nodular goitre with cystic degeneration but no malignancy. Subsequent regu-
lar monitoring with serial TFT showed development of subclinical hypothyroidism which
progressed over a span of two years to overt hypothyroidism requiring LT4 replacement as
she fatigued readily and put on weight easily.Her computed set point was FT4 = 14.0 pmol/L and TSH = 1.35 mU/L which matched
her original TFT very closely (Figure 10).
Case examples when original normal euthyroid set point is unavailable
In the common clinical setting when patients with either hyperthyroidism or hypothyroidism
present to the medical doctor, there is no prior TFT done by the patient previously before the
disease onset. As such, the set point theory can be put to the acid test to evaluate if the patients’
health outcomes are optimized or improvedwhen their thyroidmedications are dose titrated till
the their TFTs approach the computed set points.
Figure 11 Set point tracing of patient P19 (NWC).
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This man was diagnosed with Graves’ disease in February 2002 when he pre-
sented with thyrotoxic periodic paralysis associated with severe hypokalemia
(plasma potassium = 1.8 mmol/L) due to transcellular potassium shift precipitated
by hyperthyroxinemia.His initial TSH receptor antibody (TRAb) level was 9.7 U/L. After 46 months of
daily propylthiouracil (PTU) therapy, he was weaned off PTU completely when TRAb
became undetectable and has remained euthyroid ever since December 2005. Regular
follow-up revealed stable TFTs with FT4 ~ 11–13 pmol/L and TSH ~ 1.3-1.9 mIU/L
approximately. These values may be reflective of his original HPT axis euthyroid set
point. Using our minimal model, his set point was computed as: FT4 = 11.58 pmol/L
and TSH = 1.86 mIU/L (Figure 11). This predicted set point agrees closely with our
clinically observed euthyroid estimates. Indeed, he felt positively nursed back to
health state at this present time.
Analyzing the loop gain at this predicted set point using control theory and applying
equation (2.3.4), we have:
GL ¼ GHPGTj j ¼ φ TSH½ αA exp −α TSH½ ð Þ
¼ 0:3782ð Þ: 1:86ð Þ: 0:538ð Þ: 18:32ð Þ: exp −0:538ð Þ: 1:86ð Þ½ 
¼ 2:55
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set point is stable in this patient’s HP control system.Case 2: 77 yr old Chinese woman P22 (LBG)
This elderly woman presented with classical primary hypothyroidism due to Hashimoto’s
thyroiditis, including weight gain, lethargy, cold intolerance, dry skin and constipation. Her
serum thyroperoxidase autoantibodies (TPO Ab) exceeded 500 IU/L and anti-thyroglobulin
(anti-Tg Ab) titre was greater than 102,400. She was initiated on L-T4 replacement at 25
mcg daily and titrated gradually to 100 mcg daily. Unfortunately, she had memory lapses
which led to suboptimal compliance to L-T4 dosing as we subsequently discovered. Hence,
her L-T4 dose was eventually fixed at 100 mcg daily till she finally attained clinical and
biochemical euthyroidism.She persistently experienced cold intolerance despite TFTs within the normal
ranges. Remarkably, she felt normal for the very first time when FT4 = 17 pmol/L
and TSH = 0.99 mIU/L was attained through full medication compliance, thus
implying this to be her euthyroid set point. This agrees closely with the com-
puted set point: FT4 = 16.26 pmol/L and TSH = 1.63 mU/L (Figure 12). The loop
gain at the set point is 4.11, confirming a stable position (ie. homeostatic
equilibrium).Figure 12 Set point tracing of patient P22 (LBG).
Figure 13 Set point tracing of patient P20 (LPB).
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This woman has underlying Graves’ disease on CMZ for 18 months before she underwent
total thyroidectomy. Post-operatively, she developed overt hypothyroidism while on L-T4
50 μg daily. L-T4 was thus escalated to 75 μg daily which stabilized her at FT4 = 15 pmol/L
and TSH = 1.15 mU/L and rendered her fully asymptomatic. Thus, this probably
represented her euthyroid set point though she had no pre-disease TFT to countercheck.
Her computed her set point was FT4 = 14.83 pmol/L and TSH = 1.05 mU/L (Figure 13),
which was nearly a perfect match with the observed euthyroid TFT.The calculated loop gain here equals 5.78, indicative of a very stable position of
homeostasis.Clinical evidence supporting the exponential model for set point computations
It has been established for decades that the log-linear relationship seems to operate
very well in correlating the [TSH]-[FT4] hormone pair in the HPT axis [15-21]. How-
ever, it is noteworthy that some very recent papers have surfaced that challenge this no-
tion. The models being proposed as more accurate varied from error function, fourth
power polynomials to negative sigmoidal curves with inflexion points, and are all virtu-
ally based on aggregate analyses of clinical data of hundreds of thousands of different
individuals [31-34]. Interestingly, the latter negative sigmoidal curves model has in fact
been predicted by fundamental mathematical modeling [14]. Crucially, this negative
Figure 14 Scatter plots and associated HP curves A) TSH vs. FT4 (N=70) B) log TSH vs. FT4 (N=70)
C) HP curves (N=20) and D) HP curves with individual set points (N=70).
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log-linear model when the ranges of [TSH] and [FT4] are confined to values not ex-
tending to pathological extremes associated with the phenomenon of hysteresis [14,22].
The key commonality in terms of weakness in methodology in all these recent papers
is the crude attempt to fit different mathematical functions into a fuzzy and unrelated
data cloud belonging to different individuals collectively bunched together for analysis
at the population level. This leads to the illusion that the relationship of [TSH] and
[FT4] is not a log-linear one. As such composite data introduce variations and errors
that are typically analyzed statistically using means/medians of these data aggregates,
the underlying physiological signal can be totally masked and misinterpreted due to
excessive noise superimposed on the signal [35]. As these TFT paired coordinates
looked randomly distributed, various “nonlinear models of best fit” can conceivably be
regressed through the scatter-plot (Figure 14A and B). If each person is separately ana-
lyzed, the signal-to-noise ratio is markedly improved and the negative exponential
curves become unmistakably apparent as elegantly proven when we fit the curves on
an individual basis (N = 20) (Figure 14C). In fact, in our entire case series (N = 70), all
patients’ individual TFT coupled ‘data pairs’ can be readily fitted with a negative ex-
ponential curve with a coefficient of determination (R2) well exceeding 80% which
strongly supports the parameterizable log-linear relationship (Figure 14D). In every
case, the set point can be computed accurately using this minimal negative exponential
Figure 15 Graph showing the scatter-plot of the computed set points of all cases (N = 70).
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unique and separate from one another (Figure 15). Notably, the appreciable ‘noisy scatter’
of these euthyroid TFT points (N = 70) bears no trace of resemblance to any negative ex-
ponential curve. Yet, an individualized HP curve remarkably passes through each of these
set points (Figure 14D). It cannot be overemphasized that basic physiological laws and
principles have always been traditionally investigated and enunciated precisely by physiol-
ogists at the individual cellular, tissue or organismal level as epidemiological and statistical
methods are fundamentally flawed approaches to unravel such biological signals and rela-
tionships with any degree of accuracy and confidence.
Corroboration from an animal model
We acknowledge that we were unable to induce thyrotoxicosis and hypothyroidism in
healthy human beings with intact HPT axis operating in a closed loop to demonstrate
the precision of our set point theory. This clinical experiment itself is not without risks
and poses definite bioethical issues which limit our ability to prove the construct the
HP curves and apply the set point theory using perfectly healthy human controls. How-
ever, one of the author (MKSL) who is a clinician scientist have conducted experiments
with SICS (A*STAR) scientists using healthy wild-type adult male C57BL/6 inbred mice
in our investigations of perturbing the HPT axis in a murine model. Animal care and
experimentation were in accordance with the Guidelines for the Care and Use of
Laboratory Animals and were ethically approved by the Institutional Animal Care and
Use Committee, Biological Resource Centre (IACUC #120723), Singapore. These mice
were housed in husbandry under conventional conditions (23°C, 50%–60% humidity
and condition) and maintained with free access to food and water under a 12-h
light/dark cycle in compliance to the guidelines of the National Advisory Committee
for Laboratory Animal Research (NACLAR) of Singapore. The protocol for induc-
tion of hypothyroidism was 0.15% 6-n-propyl-2-thiouracil (PTU) in low iodine chow
(TD.95125 from Harlan Laboratories) for 28 days. For induction of thyrotoxicosis,
adult mice were treated with intraperitoneal 5 μg of L-T3 (3,3’,5-triiodo-L-thyronine
Figure 16 Computation of set point using a C57BL/6 healthy mouse model.
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set point and showed that the dataset from a mouse model (serum total T3 in ng/dL and
mouse TSH in mU/L) is valid with a goodness-of-fit (R2) of 88% (Figure 16). This implies
that the maximum curvature theory may be applicable across a wider species of verte-
brates and hence may also be used by veterinary doctors and zoologists.Discussion
The treatment of patients with hyperthyroidism and hypothyroidism worldwide for
many decades till this day has continued to be the enduring clinical practice of titrating
the appropriate thyroid medication in order to achieve the therapeutic objective of bio-
chemical euthyroidism as defined by the attainment of [FT4] and [TSH] within the nor-
mal population reference limits [36,37]. However, this well established strategy has only
recently been subject to scrutiny and critique due to many thyroid patients who persist-
ently complained of residual symptoms despite being rendered ‘euthyroid’ according to
the above criteria [4-8], an enigma that challenges the existing notion of what exactly is
euthyroidism itself. Distinct time lags between TSH gene expressions levels in response
to ambient [FT4] concentrations related to epigenetic modifications is one mechanism
that accounts for such a perplexing disparity [38]. Another equally important contribu-
tory factor to these distressing incongruent clinical outcomes is the differential recovery
rates in the spatiotemporal attainment of equilibrium between molecular, cellular,
tissue, organ, systemic and biochemical euthyroidism, currently a subject of intense
research [7,39]. Clearly, this remains an unresolved scientific issue by the yardstick of
our present state of knowledge. But assuming that all these compartments have in fact
equilibrated stably and are equally euthyroid after a finite span of time, any residual
dysthyroid symptoms imply that the state of euthyroidism is not closely aligned to the
patient’s personal homeostatic set point. It is this area of treatment-outcome incongru-
ence that we specifically develop our theory to exact an effective remedy.
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[FT4] and [TSH] that remain relatively constant across time implied that the normal
intra-individual euthyroid ranges of [FT4] and [TSH] must be significantly narrower
than the population reference ranges and suggest that every human being has an indi-
vidualized ‘set point’ dictated by the HPT axis as the healthy euthyroid point around
which physiological oscillatory variations may occur [1,4]. Thus, the diurnal variations
in [FT4] and [TSH] can be visualized as stable miniature hormonal oscillations around
the physiological set point analogous to a ball rolling back and forth in a conical cup
where the bottom of the cup is the ‘center of gravity’ representing the stable euthyroid
set point. In fact, the proper operation of negative feedback loops in metabolic physi-
ology necessitates homeostatic set points that the biological system inherently possesses
and targets towards for the maintenance of functions critical to survival of the organism.
Hence, though this set point approach to manage thyroid patients seems to be a relatively
unsettled concept, it is based on physiological principles firmly grounded in the biomed-
ical literature on various aspects of endocrine regulatory feedback loops [9,11,12].
Our mathematical model of the set point provides credible evidence that this should
occur at the position corresponding to the point of maximum curvature on the nega-
tive exponential HP curve. This location offers the greatest efficiency for ultra-fine
sensitivity of the thyrotrophs to calibrate their [TSH] response robustly to any changes
in [FT4]. Remarkably, the second derivative of the curvature function shows a natural
tendency for the thyroid secretion of [FT4] to hover tightly in the region encompassing
the neighborhood of this set point, and optimal control analysis independently con-
firmed the high stability of the set point based on maximal loop gain with respect to
[TSH] over this spot. Sensitivity analysis revealed that the set point computation based
on the parameters S and φ is reasonably precise with appreciable estimation errors only
when [FT4] and [TSH] are distant from the normal ‘euthyroid’ ranges (ie. < 3 pmol/L
and 0.5 mU/L respectively), thus guaranteeing that predicted euthyroid set points oc-
curring within the reference ranges are likely to be accurate. Thus, for all intent and
purposes, our model should yield predicted HPT set points that are sufficiently robust
and reliable for routine clinical applications.
To the best of our knowledge, our mathematical theory of the HPT set point is novel
and radical, being the very first of its kind ever to have been proposed in the thyroidol-
ogy literature as there are no parallel conjectures forwarded or published by anyone
else to date comparable with ours. The case examples provided cogent proof by directly
confirming the observed human data against the matched euthyroid set points as
predicted by our theoretical calculations. Indeed, the difference between the patients’
presumed set point [FT4] and the estimated set point [FT4] varied from as low as 0%
to about 16% while that for [TSH] varied between 0% to about 38%. In contrast,
given the wide population normal ranges in TFT, our present clinical practice can
grossly under-estimate or over-estimate the true set point by as much as about 80%
and 400% for [FT4] and [TSH] respectively depending on the circumstances. This
probably accounts for the commonly observed phenomenon of numerous people
who still complain of persistent dysthyroid symptomatology even though they have
TFT values falling within the normal ranges.
In conclusion, we have developed a rigorous theoretical framework for computation of
the HPT axis set point of any individual which can be used to assist clinicians in the
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more precisely target their doses of thyroid medications so as to attain TFTs that fall within
the set point region predicted by the theory. Obstacles that have hindered widespread adop-
tion of mathematical calculations among healthcare professionals still abound. But such bar-
riers are gradually eased with the increasing acceptance of computer technology among
medical doctors in the modern era. While these calculations may seem cumbersome, we
have patented a computerized algorithm currently developed into software (Thyroid-SPOT:
Set Point Optimization and Targeting) to greatly facilitate the euthyroid set point determin-
ation [40]. We envisage that this computer program can be readily implemented and ap-
plied in the clinic and hospital settings for optimal outcomes that many with thyroid
disorders will stand to benefit in the age of personalized medicine.
Limitations
We recognize the lack of a randomized clinical trial to prove the superiority of such a
set point-targeted approach over the standard ‘normal range guided’ treatment. A pro-
spective clinical trial using the set point theory as developed above can be employed in
future to confirm if patients randomized to a set point-centric approach will have better
clinical outcomes compared to those treated using the standard conventional approach.
As well, because the construction of an accurate HP curve requires multiple TFT data
points, it means that it could take at least 3–6 months before the set point can be esti-
mated. Using only 2–3 paired [FT4]-[TSH] data points obtained at the initial phase of
treatment to deduce the set point is thus unlikely to generate an accurate prediction
due to possible confounding hysteresis factors likely to operate in the early stages of
treatment of either severe hyperthyroidism or hypothyroidism.
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